Received May 19, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARCEL | VARICELLA (VARIVAX) | MERCK & CO. INC. | UNK | — | — |
| VARCEL | VARICELLA (VARIVAX) | MERCK & CO. INC. | UNK | — | — |
No additional AE reported; 17 month old patient was administered MMR II & VARIVAX today, 15-May-2026. After the patient left, the mother called back and reported that patient had already received MMR II & VARIVAX at 12 months.; This Spontaneous report was received from physician and referred to a 17-month-old patient of unknown gender. The patient's medical history was not reported. The patient's past medications were not reported. The patient's concomitant medication included measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live powder and solvent for solution for injection (M-M-R II). The vaccine was reconstituted with sterile diluent (MERCK STERILE DILUENT). In approximately 2025 (reported as at 12 months), the patient received Varicella Virus Vaccine Live (Oka-Merck) powder and solvent for solution for injection (VARIVAX) (formulation, strength, dose, route, lot# and expiration date were not reported) for prophylaxis. The vaccine was reconstituted with sterile diluent (MERCK STERILE DILUENT) (lot# and expiration date were not reported). On 15-MAY-2026, the patient received Varicella Virus Vaccine Live (Oka-Merck) powder and solvent for solution for injection (VARIVAX) (formulation, strength, dose, route, lot# and expiration date were not reported) for prophylaxis (Product administered to patient of inappropriate age). The vaccine was reconstituted with sterile diluent (MERCK STERILE DILUENT) (lot# and expiration date were not reported). No additional adverse event (AE) reported (No adverse event). Lot# is being requested and will be submitted if received.
M-M-R II; M-M-R II; STERILE DILUENT; STERILE DILUENT